SPOTLIGHT: NJ to take the brunt of Schering's cuts

Fasten your seat belts, New Jersey, it's going to be a bumpy ride. Schering-Plough CEO Fred Hassan said that the budget ax will fall hardest in New Jersey as the company cuts more than $1 billion in spending. Report

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.